⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

March 28, 2024Journal of Comparative Effectiveness ResearchOpen Access

R WE ready for reimbursement? A round up of developments in real-world evidence relating to health technology assessment: part 15

Alejandra Castañón Benjamin Bray Sreeram V Ramagopalan

View Full Paper

Ask AI

Bookmark

Share

Abstract

In this latest update we discuss real-world evidence (RWE) guidance from the leading oncology professional societies, the American Society of Clinical Oncology and the European Society for Medical Oncology, and the PRINCIPLED practical guide on the design and analysis of causal RWE studies.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Castañón et al. (2024) studied this question.

synapsesocial.com/papers/68e71edfb6db643587698af2 https://doi.org/10.57264/cer-2024-0033

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1R WE ready for reimbursement? A round-up of developments in real-world evidence relating to health technology assessment: part 27Review · 2026
2R WE ready for reimbursement? A round-up of developments in real-world evidence relating to health technology assessment: part 212025 · 4 citations
3R WE ready for reimbursement? A round-up of developments in real-world evidence relating to health technology assessment: part 24Review · 2026 · 1 citations
4R WE ready for reimbursement? A round-up of developments in real-world evidence relating to health technology assessment: part 28Systematic Review · 2026
5R WE ready for reimbursement? A round-up of developments in real-world evidence relating to health technology assessment: part 25Human Clinical Trial · 2026 · 1 citations

More related papers

R WE ready for reimbursement? A round-up of developments in real-world evidence relating to health technology assessment: part 262026
R WE ready for reimbursement? A round-up of developments in real-world evidence relating to health technology assessment: part 222025
Real-world evidence in the reassessment of oncology therapies: payer perceptions from five countries2024

More from Journal of Comparative Effectiveness Research

Methodological considerations for indirect treatment comparisons of HIV incidence for long-acting injectable pre-exposure prophylaxisThu,
Real-world cost-effectiveness of sequential therapy of in-class transition to ixazomib versus daratumumab for transplant-ineligible newly diagnosed multiple myeloma in ChinaTue,